Price movement over the last 24 hours
Abeona Therapeutics Inc vs NRG Energy Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while NRG Energy Inc trades at $137.14 (market cap $29.12B). The key difference: NRG Energy Inc is far larger — about 78× Abeona Therapeutics Inc's market cap, and NRG Energy Inc pays a 1.38% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NRG | |
|---|---|---|
Market Cap | $373.32M | $29.12B |
Sector | Health | Utilities |
52-Week High | $7.23 | $184.03 |
52-Week Low | $4.17 | $120.65 |
Enterprise Value | $228.22M | $52.95B |
Dividend Yield | — | 1.38% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NRG Energy trades at $138.01, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $30.71B revenue and $864M net income, though Q1 2026 earnings missed expectations. Valuation metrics show a high P/E ratio of 154.96 but attractive P/S of 0.87. Recent corporate actions include a $0.48 dividend payment in May 2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings, though elevated debt levels and recent earnings miss pose risks. The stock offers value through reasonable sales multiples and dividend income, but investors should monitor execution on 2026 EBITDA guidance of $5.3-5.8B and manage exposure to energy market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →